Biocompatibles faces a long climb back to regain share values but may succeed in the longer term
This article was originally published in Clinica
Executive Summary
Biocompatibles, the former high-flying UK biotechnology company whose share price is now trading at around one-tenth of its peak value, is unlikely to see much improvement in its stock market performance in the near future, say UK analysts.